<DOC>
	<DOCNO>NCT02122003</DOCNO>
	<brief_summary>- Retrospective study show Sorafenib 's efficacy second line treatment Tyrosine Kinase Inhibitor ( TKI ) . - Currently standard treatment 2nd line patient treat first line pazopanib metastatic Renal Cell Carcinoma ( mRCC ) . - With trial evaluate efficacy sorafenib second line treatment patient treat pazopanib mRCC .</brief_summary>
	<brief_title>Second Line Sorafenib After Pazopanib Patients With RCC</brief_title>
	<detailed_description>- Retrospective study show Sorafenib 's efficacy second line treatment TKI : AXIS study show sorafenib activity , term Overall Response Rate ( ORR ) , absence statistically significant difference Overall Survival ( OS ) 2 arm , although significant OS increase 1.4 month Axitinib arm . The INTORSECT study ( temsirolimus v sorafenib 2nd line sunitinib ) n't demonstrate statistically significant difference Progression Free Survival ( PFS ) , show OS increase patient treat sorafenib . - The COMPARZ study demonstrate non-inferiority pazopanib v sunitinib 1st line treatment mRCC . - Currently standard treatment 2nd line patient treat first line pazopanib mRCC . - Primary objective : evaluate efficacy sorafenib ( PFS ) second line treatment patient treat pazopanib mRCC . - Secondary objective : To evaluate safety sorafenib patient previously treat pazopanib . To evaluate Overall Survival . To evaluate Quality Life specific questionnaire ( FKSI-19 ; European Organization Research Treatment Cancer quality life questionnaire -C30 ) .To assess predictive role PFS OS arterial blood pressure increase baseline week 4 8 start treatment sorafenib . To assess predictive role PFS OS hand-foot syndrome week 4 8 start treatment sorafenib .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age ≥ 18 year Patients histological diagnosis Renal Cell Carcinoma ( RCC ) Measurable disease Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Life expectancy least 12 week . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; = 10.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; = 100,000/ml Total bilirubin ≤ 1.5 time upper limit normal ALT AST ≤ 2.5 x upper limit normal Alkaline phosphatase ≤ 4 x upper limit normal prothrombin timeinternational normalize ratio /partial thromboplastin time ≤ 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . ] For patient warfarin , close monitoring least weekly evaluation perform , international normalize ratio stable base measurement predose , define local standard care . Prognosis accord Heng : good intermediate Previous treatment pazopanib Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial two week completion trial . Signed informed consent must obtain prior study specific procedure First line treatment metastatic RCC pazopanib . History cardiac disease : congestive heart failure &gt; New York Heart Association class 2 ; active CAD ( MI 6 mo prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension ( &gt; = 160 mmHg systolic and/or 90 mmHg diastolic ) . History HIV infection Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) Brain meningeal metastasis Patients seizure disorder require medication ( steroids antiepileptic ) History organ allograft Patients evidence history bleed diathesis Patients undergoing renal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>sorafenib</keyword>
	<keyword>pazopanib</keyword>
	<keyword>cross-resistance</keyword>
	<keyword>TKI</keyword>
	<keyword>mRCC</keyword>
</DOC>